PER1 promotes functional recovery of mice with hindlimb ischemia by inducing anti-inflammatory macrophage polarization

Yang, Ding; Wan, Shengyun; Ma, Long; Wei, Kaikai; Ye, Kun

doi:10.1016/j.bbrc.2023.01.001

Cited by 5 publications

(7 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effects were partially blocked by deficiency in miR‐34c, suggesting an important role in promoting angiogenesis. Other approaches of promoting M2 polarisation of macrophages have also been reported to promote blood flow recovery in C57BL/6 mice as discussed earlier 20 …”

Section: Targets For Treating Limb Ischemia From Findings Of Recent R...mentioning

confidence: 96%

“…Riociguat 43 and praliciguat 44 Trimetazidine 46 Period circadian regulator 1 20 Hepatocyte growth factor 48,49,61 Bone marrow derived stem cells 50 Umbilical cord blood platelet gel 51 High frequency spinal cord stimulation 52…”

Section: Targets To Downregulate or Inhibitmentioning

confidence: 99%

“…to promote blood flow recovery in C57BL/6 mice as discussed earlier. 20 Nitric oxide (NO) release promotes angiogenesis and arteriogenesis. 40,41 The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide was reported to upregulate endothelial nitric oxide synthase (eNOS) in C57BL/6 mice with hyperglycemia and was shown to improve limb blood flow.…”

Section: Local Effects Within the Vasculature And Ischaemic Limbmentioning

confidence: 99%

See 2 more Smart Citations

Recent developments in targets for ischemic foot disease

Golledge

Thanigaimani

Barratt

et al. 2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diabetes is a key risk factor for ischaemic foot disease, which causes pain, tissue loss, hospital admission, and major amputation. Currently, treatment focuses on revascularisation, but many patients are unsuitable for surgery and revascularisation is frequently unsuccessful. The authors describe recent research in animal models and clinical trials investigating novel medical targets for ischaemia, including theories about impaired wound healing, animal models for limb ischaemia and recent randomised controlled trials testing novel medical therapies. Novel targets identified in animal models included stimulating mobilisation of CD34+ progenitor cells through upregulating oncostatin M or microRNA‐181, downregulating tumour necrosis factor superfamily member 14, or activating the Wingless pathway. Within the ischaemic limb vasculature, upregulation of apolipoprotein L domain containing 1, microRNA‐130b or long noncoding RNA that enhances endothelial nitric oxide synthase expression promoted limb blood supply recovery, angiogenesis, and arteriogenesis. Similarly, administration of soluble guanylate cyclase stimulators riociguat or praliciguat or 3‐ketoacyl‐CoA thiolase inhibitor trimetazidine promoted blood flow recovery. Translating pre‐clinical findings to patients has been challenging, mainly due to limitations in clinically translatable animal models of human disease. Promising results have been reported for administering plasmids encoding hepatocyte growth factor or intra‐arterial injection of bone marrow derived cells in small clinical trials. It remains to be seen whether these high resource therapies can be developed to be widely applicable. In conclusion, an ever‐expanding list of potential targets for medical revascularisation is being identified. It is hoped that through ongoing research and further larger clinical trials, these will translate into new broadly applicable therapies to improve outcomes.

show abstract

Section: Targets For Treating Limb Ischemia From Findings Of Recent R...mentioning

confidence: 96%

Section: Targets To Downregulate or Inhibitmentioning

confidence: 99%

Section: Local Effects Within the Vasculature And Ischaemic Limbmentioning

confidence: 99%

See 1 more Smart Citation

Recent developments in targets for ischemic foot disease

Golledge

Thanigaimani

Barratt

et al. 2023

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

“…1,4-Dihydropyridine analogs (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15) were synthesized, as previously reported in the literature by Pollo [16] (Figure 1), following the Hantzsch dihydropyridine synthesis methodology, in a one-pot manner without added catalyst. All the referred substances were purified by column chromatography and characterized by 1 H, 13 C NMR, and high-resolution mass spectrometry (HRMS).…”

Section: Compound Synthesismentioning

confidence: 99%

“…The classical pharmacological approach to the treatment of inflammatory conditions is based on the use of medicines able to reduce the synthesis of the inflammatory mediators involved. However, recent studies have focused on attempting to modulate the profile of pivotal inflammatory cells, such as macrophages and neutrophils, involved in triggering and maintaining the phenomenon [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the anti‐inflammatory effect of 1,4‐dihydropyridine derivatives

Facchin,

Lubschinski,

Moon

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

IntroductionInflammation is a physiological event that protects the organism against different factors that lead to loss of tissue homeostasis. Dihydropyridine (DHP) derivatives are heterocyclic compounds known for their different biological activities, including anti‐inflammatory activities.ObjectiveTo evaluate the anti‐inflammatory activity of 1,4‐dihydropyridine (1,4‐DHP) derivatives using anti‐inflammatory models in vitro, in RAW264.7 cells induced by lipopolysaccharide (LPS) and in vivo using the acute lung injury (ALI) model in mice.ResultsFifteen compounds derived from 1,4‐DHP were tested in RAW264.7 cells for their cytotoxic effect and cell viability. Thereafter, only the six compounds that showed the highest cell viability were tested for the production or inhibition of the pro‐inflammatory cytokine interleukin 6 (IL‐6). The best compound (compound 4) was tested for its anti‐inflammatory effects in vitro and in vivo, showing inhibition of nitric oxide (NO), pro‐inflammatory cytokines, increased phagocytic activity, and an increase in IL‐10 in vitro. In in vivo tests, compound 4 also reduces the levels of NO, myeloperoxidase (MPO) activity, leukocyte migration, and exudation, as well as reducing the levels of tumor necrosis factor‐alpha (TNF‐α) and IL‐6 and preventing the loss in the lung architecture.ConclusionThis compound showed important anti‐inflammatory activity, with a significant ability to reduce the production of pro‐inflammatory mediators and increase the phagocytic activity of macrophages and anti‐inflammatory mediator secretion (IL‐10). These findings led us to hypothesize that this compound can repolarize the macrophage response to an anti‐inflammatory profile (M2). Moreover, it was also able to maintain its anti‐inflammatory activity in vivo experiments.

show abstract

Pathology, Progression, and Emerging Treatments of Peripheral Artery Disease–Related Limb Ischemia

Golledge

2023

Clinical Therapeutics

View full text Add to dashboard Cite

PER1 promotes functional recovery of mice with hindlimb ischemia by inducing anti-inflammatory macrophage polarization

Cited by 5 publications

References 43 publications

Recent developments in targets for ischemic foot disease

Recent developments in targets for ischemic foot disease

Evaluation of the anti‐inflammatory effect of 1,4‐dihydropyridine derivatives

Pathology, Progression, and Emerging Treatments of Peripheral Artery Disease–Related Limb Ischemia

Contact Info

Product

Resources

About